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RT-qPCRHorn cancer accounts for nearly 83% of total tumors found in Indian Zebu cattle, which results in chronic
suffering and causes heavy economic losses. Alternative splicing has been frequently implicated in the var-
ious types of cancer progression. Utilizing the transcriptome sequence generated by next generation se-
quencing, we analyzed the transcript data for the presence of alternative splicing using BLAT program
and identiﬁed 27 alternatively spliced genes, of which 12 spliced variants appeared to be the novel spliced
candidates. Protein prediction of these novel spliced variants revealed that splice variation has caused ei-
ther truncation of protein, insertion/deletion of stretch of amino acids or formation of unique carboxy ter-
minus. The RT-PCR analysis conﬁrmed the expression of 8 of the 12 novel spliced variants observed by
transcriptome sequencing. Additionally, altered splicing/expression of these novel candidates between
cancer and normal tissues revealed by qPCR suggests their potential involvement in the development of
horn cancer.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
Horn cancer, a type of squamous cell carcinoma, is very common
in Kankrej breed of cattle in India accounting about 83% of total tu-
mors reported [1,2]. It leads to a heavy economic loss due to reduc-
tion in draught power, chronic morbidity and mortality of animals.
Recently, we reported the preliminary transcriptome analysis of
horn cancer in Indian zebu cattle (Kankrej breed), identifying differ-
ential expression of potential cancer associated transcripts [3].
Cancer progression is characterized by altered gene expression
pattern, differential splicing, expression of novel transcripts and genetic
alterations [4–6]. The splicing of pre-mRNA is often deregulated in
cancer [4,7]. The different spliced isoforms resulting from inherited or
acquired changes in splicing have been reported in various human
cancers [8–10]. Moreover, the experimental veriﬁcation of the effect
of mutations at DNA or RNA level revealed about 50% of the mutations
resulting in the aberrant splicing [11,12].BLAST Like Alignment Tool;
ormal; HC, horn cancer; NGS,
on- polymerase chain reaction;
lymerase chain reaction.
rights reserved.Alternative splicing (AS) is the major fundamental mechanism
generating the protein diversity and regulating the gene expression
in eukaryotic organism [13,14]. The pre-mRNA undergoes splicing
in the nucleus where after removal of intronic sequences, exons are
joined in different combinations, leading to generation of isoforms
with distinct transcript structure. The proteins thus encoded by transcript
isoforms vary in their structures aswell as functions. This alteration in the
protein structure and function resulting from aberrant or AS is commonly
associated with diseases [6].
The comparative analysis of cancer and normal tissue by micro-
array and RT-qPCR provides substantial information about their
gene expression proﬁle; however, it is unable to identify the differ-
ences at nucleotide level. The changes in the expression pattern are
more likely a consequence of genetic alteration acquired by tumor
cells. Hence, studying the expression pattern along with generating
the information at nucleotide levelwouldhelp todecipher theunderlying
mechanism leading to cancer progression. Next generation sequencing
(NGS) approaches make it feasible by providing single nucleotide level
resolution [15].
In earlier study [3], we generated de novo sequence data for horn
cancer and surrounding normal tissue transcriptome employing
Roche's 454 NGS technology. In the present study, we aimed to identify
and validate novel transcript variants in the horn cancer and normal tis-
sue, which may predispose or leads to horn cancer in Kankrej breed of
cattle.
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2.1. Transcriptome sequencing identiﬁed novel splice variants in horn
cancer and normal tissues
BLAT analysis resulted in the identiﬁcation of 27 alternatively
spliced transcripts, which consisted in six variants of exon skipping,
six exon insertion, one intron retention, six 5′ AS, ﬁve 3′ AS, one exon
insertion and 3′ AS together, one exon skipping and insertion and one
5′ as well as 3′ AS. Fig. 1 shows the unique splice variants in DERL3
gene. The respective ﬁgures of other splice variants identiﬁed are pro-
vided in Supplementary ﬁle 1. Among the 27 variants identiﬁed in the
present study, 15 variants matched with their respective homolog al-
ready reported for different species upon BLAST analysis (Table 1).
However, 12 splice candidates were found novel as they did not
match with any sequence in the database upon BLASTN analysis
(Table 2). Splice site motif analysis of unique splice candidates showed
that all novel splice variants follow the GT-AG rule of splicing.
2.2. Translation of novel splice candidates reveals protein structural
variations including premature terminations, insertions and deletions
Translation of unique splice candidates by Translate tool and their
comparison with reference protein sequences using NCBI protein blast
revealed variations in the protein sequence. These variations resulted
from frame shift inmRNAdue to inclusion or exclusion of exon, alterna-
tive 5′ or 3′ splice site selection or intron retention, leading to termina-
tion of protein chain (ITGA5, DLX4, SLC35F5, MTGA4B, and RFXANK),
insertion (LAG3) or deletion of stretch of amino acids (a.a.) (ACIN1,
DERL3, OLFML2B, ZNF622, EVI5L, and PYCR2), or formation of unique
carboxy terminal domain (ITGA5, DLX4, MTGA4B, and RFXANK). The
details about the variation in the protein sequence for all unique splice
candidates due to AS are given in Table 2.
2.3. RT-PCR analysis of novel spliced candidates validated expression of
8 of the 12 novel variant isoforms
In order to validate our ﬁndings, all the 12 novel splice variants were
subjected to RT-PCR for both HN and HC samples. The RT-PCR analysis
conﬁrmed expression of 8 out of the 12 novel spliced candidatesFig. 1. BLAT analysis showing exon skipping and 3′ alternative splicing (AS) in contig HC00761
theOctober 2007 assembly, available at http://genome.ucsc.edu [32], with the exon/intron struc
ing regions indicated below. Conserved regions are indicated by blue bars. AS is indicated by
shows skipping of exons 3 and 4 (indicated by square tailed arrow), and 3′ AS in exon 5 (indic(indicated by arrows) as observed by the agarose gel electrophoresis
of RT-PCR ampliﬁed products (Fig. 2). The expression of EVI5L,
OLFML2B, LAG3 and ZNF622 variant isoforms could not be validated
by variant speciﬁc primer sets. However, the reference isoform of the
corresponding genes was ampliﬁed for all 12 target genes (indicated
by round tailed arrows). The expected size ampliﬁcation corresponding
to both reference and variant isoform of OLFML2B could be observed
(Fig. 2) with primer set designed ﬂanking the novel splice junction.
2.4. Altered splicing/expression of transcripts between horn cancer and
normal tissue as revealed by RT-qPCR
In addition to conﬁrmation of expression of variant isoforms, we
studied relative expression of reference and variant isoform in four
horn cancer samples compared to normal horn tissue by RT-qPCR,
which revealed differential expression of reference and variant
isoforms between horn normal and cancer tissues (Fig. 3). Among
the 12 candidate genes, the EVI5L reference isoform and RFXANK
variant isoform were up-regulated in all four cancer samples where-
as the reference isoform of the eight target genes viz. ACIN1, ITGA5,
DERL3, SLC35F5, RFXANK, ZNF622, DLX4 and LAG3 and variant iso-
form of the three target genes viz. ACIN1, MGAT4B and PYCR2 were
down-regulated in all four cancer samples. The expression of
OLFML2B reference isoform was inconsistent with up-regulation in
one of the four cancer samples. The quantitative comparison of the
other isoforms between normal and cancer tissues could not be
assessed due to ampliﬁcation of multiple products in addition to
expected ampliﬁcation (Fig. 2).
3. Discussion
Alternative or aberrant splicing is frequently associated with cancer
and may result from cis-acting mutations in the intronic dinucleotides
i.e. GT and AG ﬂanking the exons, mutations in the exonic splicing en-
hancers, mutations creating cryptic splice site signals or by altered ex-
pression of trans-acting splicing regulatory factors [4]. The differential
expression of various spliced isoforms in cancer compared to normal
cells is likely to play a signiﬁcant role in determining the phenotype of
a cancer cells. In the present study, we found 27 alternatively spliced
genes from total of 9900 contigs. From these, 15 splice variations are. Image is acquired from the University of California at Santa Cruz Genome Browser, using
ture of each gene indicated at the top and themammalian conservation of the correspond-
arrows; exon positions of the reference sequence are numbered above the contig. Figure
ated by dotted line arrow), in the DERL3 gene corresponding to contig HC00761.
Table 1
List of genes in which alternative splicing observed in horn tissue and the matching sequence isoform in the NCBI non-redundant (nr) and expressed sequence tag (EST) database.
Contig (length), accession number Sequence reads Gene Organism % Identitya Accession number of matched sequenceb
HC001796 (1970bases), JT907437.1 53 FHL1 Bos taurus 99 NM_001113259.1
Bos taurus NM_001113258.1
Bos taurus NM_001034341.1
HC02878 (253bases), JT908499.1 6 PQLC Sus scrofa 83 NM_001243851.1
HC00892 (2422bases), JT906552.1 55 LTBASES2 Sus scrofa 82 XM_003128665.3
HCN02150 (512bases), JT912724.1 6 SIPA1 Bos taurus 96 NM_001101895.1
HC00697 (923bases), JT906359 8 KLF6 Bos taurus 99 NM_001035271.2
HC00068, (956bases), JT905741.1 14 KCNN4 Canis lupus familaris 93 XM_541579.2
HC04086 (575bases), JT909522 6 LASS5 Canis lupus familaris 88 XM_534805.3
HC04564 (615bases), JT909923 7 PITPNB Homo sapiens 91 BC031427.1
HC02421 (592bases), JT908050.1 7 GRINA Bos taurus 99 NM_001037593.1
HC03634 (890bases), JT909141 10 U2AF2 Homo sapiens 90 NM_001012478.1
HCN02555 (493bases), JT913063.1 6 DNAJB12 Sus scrofa 94 XM_001924319.2
HCN02180 (244bases), JT912751.1 2 UQCRC1 Pan troglodytes 99 XM_516440.3
HCN001675 (232bases), JT912388.1 8 FABASES5 Homo sapiens 99 NG_009321.1
HCN00192 (637bases), JT910943.1 18 PICALM Canis lupus familaris 97 XM_852735.2
HC04970 (591bases), JT910250 6 ZZZ3 Bos taurus 99 DT721643.1
a Percentage homology of the contigs with the matched sequence in the NCBInr and est databases.
b Accession number of the corresponding sequence, matching with the contig, in the NCBInr and EST database.
59A.K. Patel et al. / Genomics 101 (2013) 57–63already reported (Table 1),whereas the 12 splice variants did notmatch
with any mRNA or EST sequences currently available in the database
(Table 2). Further inspection of intronic splice donor and acceptor
sites of novel splice variants revealed presence of GT and AG sequencesTable 2
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followed GT-AG rule of splicing. Protein prediction of these 12 novel
candidates revealed splice variation has caused either truncation of pro-






Protein chain Reference protein
accession number
01 629 16–87 (72) a.a. deleted NP_001098880
b
85 200 From 153 position, 48 new a.a.
formed and then protein truncated
NP_001159972
31 134 54–150 (97) a.a. deleted NP_001069791
55 229 Change in reading frame, c-terminal
a.a. 156–229 (74) unique
NP_001091510
59 435 242–255 (14) aa deleted NP_001093824
70 252 206–216 (11) aa deleted NP_001029623
07 716 682–713 (32) a.a. deleted NP_001092545
24 372 7 new a.a. from position 366 and at
position 372 protein is truncated
NP_001094712




16 545 Change in the reading frame, 71–100
(30) a.a. inserted
NP_001232878
28 271 Change in the reading frame,
c-terminal 212–271 (60) a.a. unique
NP_001098958
20 260 47–106 (60) a.a. deleted NP_001068649
rter than the corresponding putative ortholog from human.
Fig. 2. RT-PCR validation of novel spliced candidates. Agarose gel electrophoresis of PCR products from horn cancer and normal tissue using isoform speciﬁc primers (Table 3) which
selectively amplify either reference or variant transcript. The expected ampliﬁcation sizes are indicated with round tailed arrows (reference isoform) and arrows (variant isoform).
Gene names indicated on the top of the lane for respective genes, where _R and _V following gene names indicate reference and variant isoforms, respectively. N and C indicate
ampliﬁcation from normal and cancer tissues, respectively. aPrimer sets were designed to amplify both isoforms. L: mass ruler low range DNA ladder (Fermentas).
60 A.K. Patel et al. / Genomics 101 (2013) 57–63c-terminal tail of variable length. The alteration in the protein sequence
may thus lead to either gain of function, loss of function or change in the
speciﬁcity of the protein and its functional diversity.
The RT-PCR analysis of horn cancer and normal tissue conﬁrmed
the expression of 8 of the 12 novel AS variants revealed by the
RNA-Seq and BLAT analysis. However, for some genes, the pattern
of expression with RT-PCR analysis differed with comparison to
RNA-Seq analysis (Table 3). The differential expression pattern ob-
served by the RNA-Seq analysis thus necessitates further validation
by alternative and more reliable methods like RT-PCR. On the other
hand, 8 of the 12 novel spliced variants identiﬁed by RNA-Seq analy-
sis were conﬁrmed by RT-PCR, demonstrating the potential to iden-
tify the alternatively spliced variants on high throughput basis.
Besides conﬁrming the expression of novel spliced candidates, the
RT-qPCR analysis revealed the differential expression of alternative
isoforms between cancer and normal tissue. Among the potential
novel transcript variants, some of the genes have been implicated in
the development of various cancers which include ACIN1 [16,17],
ITGA5 [18], DLX4 [19,20], MGAT4B [21], LAG3 [22], RFXANK [23],
SLC35F5 [24] and ZNF622 [25]. We also observed novel spliced variants
in the genes not yet implicated in cancer which include EVI5L, PYCR2,
OLFML2B and DERL3.
The validation of differential expression of AS variants in multiple
horn cancer cases may provide causative link leading to progression of
horn cancer. Hence, in this study, we aimed to analyze expression of
these transcripts in four horn cancer samples. The isoform speciﬁc
qPCR analysis revealed consistent up-regulation of EVI5L reference
transcript in all four cancer samples assessed. Although functionalimplication of EVI5L in oncogenic progression is yet to be studied, its
structural similarity with EVI5 oncogene [26] is indicative of its possible
involvement in cell proliferation. Similarly, consistent over-expression
of variant but not reference isoform was observed for RFXANK gene in
all four cancer samples. The RFXANK is a MHC class-II transcription fac-
tor which has been found to be suppressed in colorectal adenocarci-
nomas with possible implication in immunodeﬁciency of the cancer
tissues [23]. The down-regulation of reference isoform in our study is
suggestive of immunodeﬁciency in horn cancer tissue; however, evalu-
ation of the effect of over-expression of variant isoformon expression of
MHC and non-MHC genes in cancer tissue may provide signiﬁcant in-
sights into its association with cancer.
We observed signiﬁcant down-regulation of ACIN1, MGAT4B and
PYCR2 variant isoforms and ACIN1, ITGA5, DERL3, SLC35F5, LAG3,
DLX4 and ZNF622 reference isoforms in all four cancer samples. The
down-regulation of both reference as well as variant isoform for
ACIN1 was rather suggestive of its possible deregulation at the level of
transcription and may not be due to altered splicing. ACIN1 has been
shown to induce apoptotic chromatin condensation [16]. The
down-regulation of both isoforms in horn cancer may thus reduce can-
cer cell clearance through apoptosis. The expression of MGAT4B is in-
creased in pancreatic cancer [21]. The RNA-Seq expression proﬁle
(Table 3) suggests up-regulation of MGAT4B in horn cancer; however,
isoform speciﬁc qPCR revealed down-regulation (1.28- to 2.2-fold) of
MGAT4B variant isoform in all four cancer samples, whereas reference
isoform expression could not be assessed due to ampliﬁcation of multi-
ple products. The RNA-Seq analysis represents cumulative expression of
both isoforms. The PYCR2 interacts with telomere repeat binding factor
Fig. 3. RT-qPCR analysis of spliced isofoms on multiple horn cancer samples. The relative expression of reference and variant isoforms of candidate genes was analyzed in four horn
cancer tissue samples (HC1-4) relative to normal horn tissue. Gene names indicated below the columns for respective genes, where _R and _V following gene names indicate ref-
erence and variant isoforms, respectively. The logarithmic transformation of relative quantitation (log10RQ) of each candidate isoform in cancer tissues was plotted against their
expression in normal tissue. Error bar indicates standard error of mean (SEM) of triplicate qPCR reactions.
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binds to duplex telomeric DNA and is involved in the regulation of telo-
mere maintenance and DNA damage repair [27,28]. The signiﬁcance of
PYCR2 in cancer progression has not been demonstrated so far. The
down-regulation of ITGA5 observed in horn cancer is in contrast to its
reported association in cell migration and metastasis [20], whereas
the reduced expression of DERL3 in horn cancer is in accordance with
the methylation of DERL3 promoter region reported in malignant mel-
anomas [29] which is likely to reduce its expression. Similarly, reduced
expression of SLC35F5 is associated with reduced sensitivity to chemo-
therapy [24]. LAG3 deﬁnes the regulatory T-cell subset with potent
tumor suppressor potential [30] so its reduced expression in horn can-
cer may affect immune clearance of cancer cells; however, RNA-Seq
data suggest up-regulation in cancer. Unlike RNA-Seq proﬁle, the ex-
pression of DLX4 reference isoformwas down-regulated in horn cancer
tissues in the present study. The expression of the DLX4 is up-regulated
in various cancers [19,31]. The reduced expression of ZNF622 observed
by qPCR was in accordance with RNA-Seq proﬁle; however, ZNF622 is
up-regulated in colorectal cancer [25]. The expression proﬁle varies
between tumors of different tissues; hence, it is unlikely to ﬁndTable 3
The RNA-Seq expression proﬁle of the candidate genes based on reads per kilobase of
exon model per million mapped reads (RPKM). NA indicates "not applicable".








ACIN1 55.11 43.62 0.79 −1.26
DERL3 47.52 17.63 0.37 −2.69
MGAT4B 21.38 42.32 1.97 1.97
PYCR2 16.21 7.22 0.44 −2.24
RFXANK 3.62 13.43 3.71 3.71
EVI5L 8.69 11.82 1.36 1.36
ITGA5 43.66 6.82 0.15 −6.40
OLFML2B 47.37 18.92 0.39 −2.50
SLC35F5 9.28 4.30 0.46 −2.15
ZNF622 22.36 9.48 0.42 −2.35
DLX4 – 16.16 NA NA
LAG3 – 9.39 NA NAconcordance in expression of all the targets evaluated in horn cancer
with their reported association in other cancer studies. We also ob-
served discrepancy in expression proﬁle of RNA-Seq and isoform specif-
ic qPCR and since RNA-Seq data represents combined expression level
of all annotated transcripts of a gene in the database, the RNA-Seq re-
sults need to be carefully interpreted.
Among the AS variants identiﬁed by RNA-Seq analysis, the
expression of variant isoform of EVI5L, OLFML2B, LAG3, and
ZNF622 could not be validated by RT-PCR analysis. The ampliﬁcation
of expected size products corresponding to both OLFML2B reference
and variant isoform could be seen with the primer sets designed
away from the splice junctions which can amplify both isoforms
(Fig. 2). The failure to amplify the OLFML2B variant isoform by iso-
form speciﬁc primer may suggest possibility of expression of yet an-
other isoform through different splice junctions generating similar
size product. The multiple ampliﬁcation products in other target
genes are also indicative of mis-priming or expression of additional
unknown transcripts through alternative splicing.
4. Conclusions
Wehave successfully employed 454 transcriptome sequencing plat-
form to identify alternative splicing events in horn cancer of Indian
Zebu cattle. Bioinformatics analysis suggests that a range of genes
spliced differently in cancer and normal tissue which also contained
novel spliced variants not yet reported. The study describes the identi-
ﬁcation of 12 novel spliced isoforms by RNA-Seq analysis among
which variant isoforms of eight genes were conﬁrmed by RT-PCR. Fur-
ther, we demonstrated differential expression of these gene products
in horn cancer which may represent either primary cause of horn can-
cer or the consequences of the altered trans-acting regulatory splicing
factors. The investigation in multiple cancer samples conﬁrmed differ-
ential expression of reference as well as variant isoform of several can-
didate genes, although evidence supporting their involvement in cancer
are still lacking. The functional evaluation of these differentially
expressed and novel spliced candidates in the progression of cancer
would provide key insights into understanding molecular mechanism
of cancer in general and horn cancer in particular. The preferential
62 A.K. Patel et al. / Genomics 101 (2013) 57–63expression of AS variants in cancer highlights the potential mechanism
of cancer cells to take advantage of AS to produce proteins which pro-
mote cell growth and survival.
5. Material and methods
5.1. Analysis of splice variants
In the previous study [3], the total raw reads generated after pro-
cessing of sequencing data were 392,692 and 516,696 for horn normal
(HN) and cancer (HC) tissue, respectively. With minimum overlap of
20 bases and minimum identity of 90%, the GS de novo assembler
(Roche Diagnostics, USA) could assemble 102,147 and 137,314 reads
to generate 4,095 and 5,805 contigs for HN and HC, respectively. All
the transcripts were then subjected to NCBI-BLAST (RNA; megaBLAST;
E-valueb10−4; minimum threshold 90%) with Bos taurus Refseq RNA
database for homology searching and annotation. In the present study,
all contigs coding for a gene were aligned against Bos taurus genome
database (bosTau4) using BLAT web-interface of UCSC (http://
genome.ucsc.edu) [32] for ﬁnding splice variants using the default pa-
rameters, i.e. sequence similarity 95% or greater with sequence length
40 bases or more. The sequence alignment outputs were visually ana-
lyzed for splice variants. The BLAT results showing sequenceswithmin-
imum identity of 90% were included in the further analysis. Contigs
coding for genes present on multiple chromosomes were excluded
from analysis. Splice variation candidates were analyzed to identify
any reported variant isoform using BLASTN to NCBI nucleotide
non-redundant (nr) and expressed sequence tag (EST) databases. The
intron boundaries of each novel splice junctions were manually
inspected for the presence of splice donor (GT) and acceptor (AG) sites.
5.2. Protein prediction of novel spliced candidates
Genomic and reference mRNA sequences were retrieved for the
genes matching with the contigs showing the unique splicing event.
The putative transcripts with novel splice junctions were derived byTable 4
List of primers used for isoform speciﬁc quantitative PCR. The accession numbers of the refe
in Table 2. The ampliﬁcation of speciﬁc product (indicated by arrow) can be seen from Fig.
Gene Isoform Forward primer Primer sequence
ACIN1 Reference RACIN1Fwd TGACCCAGAGGTTACAGC
Variant VACIN1Fwd GCAACAGCAGAAAAGGGAG
ITGA5 Reference RITGA5Fwd CCAGGTCTCTCTTAACGGTG
Variant VITGA5Fwd CTAAACCACCCTGCTCTG
DERL3 Reference RDERL3Fwd ATGCTGGTGTACGTGTGGA
Variant VDERL3Fwd TCCGGAAGTTCCAGGCG
DLX4 Reference DLX4Fwd TCATCAAGAGCGGGAGAC
Variant DLX4Fwd TCATCAAGAGCGGGAGAC
OLFML2B Reference ROLFMFwd GCAGGAAGAAACTGTGTCC
OLFML2Ba OLFML2BFwd CTGCAGCCTACACCCATCC
SLC35F5 Reference RSLC35F5Fwd GGCCTTATTGGAACAGTGC
Variant VSLC35F5Fwd CAATGTTCTTTGGGGCTGC
MGAT4B Reference RMGAT4BFwd CCTGTTCCCCTCTCACCA
Variant VMGAT4BFwd TGCGACTGGAGCGGTTC
RFXANK Reference RRFXANKFwd AGCACCCACACTCTGCATAC
Variant VRFXANKFwd GAGGCCTTGCTGGAGAC
PYCR2 Reference RPYCR2Fwd GCAACAAGGAGACGGTCAG
Variant VPYCR2Fwd AGGAAGCTGATGGCGTTC
LAG3 Reference RLAG3Fwd ATGTACCAGAGAGTGGCTC
Variant VLAG3Fwd ATTGGAACGAGGGGACAG
ZNF622 Reference ZNF622Fwd GCGGACGTGGGACTCAG
ZNF622a ZNF622Fwd GCGGACGTGGGACTCAG
EVI5L Reference REVI5LFwd CAGCTGAACCACTCGGAC
Variant VEVI5LFwd AGCTGGAGATCCAGGTG
RPLP0 Control RPLP0Fwd GCTTCCTGGAGGGTGTCCGC
a Primer sets are designed to amplify both reference and variant isoforms.incorporating novel splice junctions after alignment with genomic and
reference mRNA sequences. The novel transcripts were then translated
to derive the encoded protein sequence using Expasy's translate tool.
The protein sequences derived from each novel spliced variant were
then aligned with the respective protein sequence and their isoforms
in the database. AS candidates not reported so far, as variant isoform,
were further validated by RT-PCR.5.3. Validation of novel spliced candidates by RT-PCR
Twelve unique splice variation candidates were validated using
RT-PCR. The total RNA isolation from horn cancer and surrounding nor-
mal tissue samples was carried out using the RNeasy mini kit (Qiagen)
following the manufacturer's protocol. Total RNA quality and quantity
was veriﬁed on NanoDrop1000 (Thermoﬁsher) and Bioanalyzer 2100
(Agilent Technology). Reverse transcription reactions were performed
with 0.5 μg of total RNA and 1 μl of random hexamer primers using
RevertAidTM ﬁrst strand cDNA synthesis kit (Fermentas) in 20-μL reac-
tions following the manufacturer's instructions. For validation of splice
events, gene speciﬁc primers were designed from the respective tran-
script sequences using Primer3 software (http://frodo.wi.mit.edu/
primer3/) (Table 4) and synthesized (Euroﬁn Genomics India Pvt. Ltd.,
India). Two sets of primers were used for ampliﬁcation of reference
and variant isoform, respectively, for each target genes. Primers speciﬁc
for reference and variant isoform were designed after aligning the var-
iant contig sequence with the reference sequence of the corresponding
genes (for accession numbers see Table 2) and incorporating the unique
splice junctions or unique exons of the respective isoform in the primer
sequence. PCR reactions were carried out with 2× PCR master mix
(Fermentas), 200 nM of each isoform speciﬁc primers and 1 μl of
cDNA template (5-fold dilution after RT reaction). The reaction mix-
tureswere subjected to initial denaturation at 95 °C for 5 min, followed
by 35 cycles each of 95 °C for 30 s, 60 °C for 30 s and 72 °C for 60 s in a
25 μl reaction volume. The PCR products were electrophoresed on 2.0%
W/V agarose gels at 80 V and visualized by UV transilluminator
(Syngene, UK).rence and variant sequences of the candidate isoforms used to design primers are given
2.
Reverse primer Primer sequence Expected
product size
ACIN1Rev CCATGGTCACTTCCTCCTTC 168 bp
ACIN1Rev CCATGGTCACTTCCTCCTTC 156 bp
ITGA5Rev CATAGACATGGTGGACAGCAG 122 bp
ITGA5Rev CATAGACATGGTGGACAGCAG 125 bp
DERL3Rev TCAGCAGCAGCCTCTTG 223 bp
DERL3Rev TCAGCAGCAGCCTCTTG 165 bp
RDLX4Rev GGAACACACTTGGGGAAG 262 bp
VDLX4Rev GTCCACATCAATGGGCTG 232 bp
OLFMRev ATCCATTCCGTGTTCACC 244 bp
OLFML2BRev AGCAAATCCATTCCGTGTTC 289/248 bp
SLC35F5Rev TGTAATGGCACAGGAGAG 214 bp
SLC35F5Rev TGTAATGGCACAGGAGAG 187 bp
MGAT4BRev CTGCAGAGTGACCGAATG 252 bp
MGAT4BRev CTGCAGAGTGACCGAATG 146 bp
RRFXANKRev CTGCAAAGCAGAACAGGTGC 202 bp
VRFXANKRev TGCCTCAGTGGTGAGATCAG 134 bp
PYCR2Rev GCCCGTCCTCCACCAAG 272 bp
PYCR2Rev GCCCGTCCTCCACCAAG 125 bp
LAG3Rev ACGGCGGCGTGGTACTC 214 bp
LAG3Rev ACGGCGGCGTGGTACTC 247 bp
RZNF622Rev GCATCCTCACATTCCAAGTC 175 bp
ZNF622Rev CCTCCTCCATGGCTTCAG 185/159 bp
EVI5LRev CGGACGACGGTAGCGAG 172 bp
EVI5LRev CGGACGACGGTAGCGAG 114 bp
RPLP0Rev CCTCGTCCGACTCCTCCGACT 288 bp
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horn cancer samples
The horn cancer tissues from four zebu cattle were obtained and ex-
amined histopathologically to conﬁrm malignant changes as described
before. The tissues were collected in RNAlater for gene expression anal-
ysis. RNA isolation, cDNA synthesis and RT-PCR were performed as de-
scribed in Section 5.3. The relative expression of the target isoformswas
analyzed by real-time PCR analysis on ABI PRISM 7500 fast real-time
PCR system (Applied Biosystems) using the Quantifast SYBR Green
PCR master mix (Qiagen). PCR reactions contained 200 nM of isoform
speciﬁc primer sets (Table 3), 1× Quantifast SYBR Green PCR master
mix, and 1 μl of template cDNA (5-fold dilution after RT reaction) in a
15 μl reaction volume. The reaction mixtures were subjected to initial
denaturation of 95 °C for 10 min followed by 40 cycles of 95 °C for
30 s and 60 °C for 1 min. The ﬁnal melt curve analysis was performed
by increasing the temperature from 45 to 95 °C with increase of 1 °C
per 30 s followed by ﬁnal hold at 20 °C. The speciﬁcity of the ampliﬁca-
tion was conﬁrmed by running PCR product on agarose gel electropho-
resis and melt curve analysis. All reactions were run in triplicate and
cycle threshold (Ct) values for target genes were normalized with
RPLP0 reference gene. The fold change in the expression of the target
genes was calculated by the formula: 2−ΔΔCt, where ΔCt=average Ct
of target gene−average Ct of endogenous control RPLP0 and ΔΔCt=
ΔCt of cancer sample−ΔCt of normal sample.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ygeno.2012.10.001.Acknowledgments
The authors wish to thank Dr. A.E. Nivsarkar, Ex-Director, National
Bureau of Animal Genetic Resources, and Dr. J. V. Solanki, Principal
and Dean, College of Veterinary Science and Animal Husbandry,
Anand, for critical reading of the manuscript.References
[1] S.P. Singh, M. Batra, G.K. Singh, Important aspects of horn cancer, Cow (2005) 32–34.
[2] B.P. Joshi, P.B. Soni, D.T. Fefar, D.J. Ghodasara, K.S. Prajapati, Epidemiological & patho-
logical aspects of horn cancer in cattle of Gujarat, Indian J. Field Vet. 5 (2009) 65–67.
[3] A.K. Tripathi, et al., A preliminary sketch of horn cancer transcriptome in Indian
zebu cattle, Gene 493 (2012) 124–131.
[4] J.P. Venables, Aberrant and alternative splicing in cancer, Cancer Res. 64 (2004)
7647–7654.
[5] C.J. David, J.L. Manley, Alternative pre-mRNA splicing regulation in cancer: path-
ways and programs unhinged, Genes Dev. 24 (2010) 2343–2364.
[6] J. Tazi, N. Bakkour, S. Stamm, Alternative splicing and disease, Biochim. Biophys.
Acta 1792 (2009) 14–26.
[7] W. Ritchie, S. Granjeaud, D. Puthier, D. Gautheret, Entropy measures quantify
global splicing disorders in cancer, PLoS Comput. Biol. 4 (2008) e1000011.
[8] Q. Tanko, B. Franklin, H. Lynch, J. Knezetic, A hMLH1 genomic mutation and asso-
ciated novel mRNA defects in a hereditary non-polyposis colorectal cancer family,
Mutat. Res. 503 (2002) 37–42.[9] R. Klinck, et al., Multiple alternative splicing markers for ovarian cancer, Cancer
Res. 68 (2008) 657–663.
[10] J.D. Hoffman, S.E. Hallam, V.L. Venne, E. Lyon, K. Ward, Implications of a novel
cryptic splice site in the BRCA1 gene, Am. J. Med. Genet. 80 (1998) 140–144.
[11] N. Lopez-Bigas, B. Audit, C. Ouzounis, G. Parra, R. Guigo, Are splicing mutations
the most frequent cause of hereditary disease? FEBS Lett. 579 (2005)
1900–1903.
[12] Y. Xing, C. Lee, Alternative splicing and RNA selection pressure–evolutionary con-
sequences for eukaryotic genomes, Nat. Rev. Genet. 7 (2006) 499–509.
[13] D.L. Black, Mechanisms of alternative pre-messenger RNA splicing, Annu. Rev.
Biochem. 72 (2003) 291–336.
[14] J.F. Caceres, A.R. Kornblihtt, Alternative splicing: multiple control mechanisms
and involvement in human disease, Trends Genet. 18 (2002) 186–193.
[15] M. Sultan, et al., A global view of gene activity and alternative splicing by deep se-
quencing of the human transcriptome, Science 321 (2008) 956–960.
[16] S. Sahara, M. Aoto, Y. Eguchi, N. Imamoto, Y. Yoneda, Y. Tsujimoto, Acinus is a
caspase-3-activated protein required for apoptotic chromatin condensation, Nature
401 (1999) 168–173.
[17] S.W. Jang, et al., Serine/arginine protein-speciﬁc kinase 2 promotes leukemia cell
proliferation by phosphorylating acinus and regulating cyclin A1, Cancer Res. 68
(2008) 4559–4570.
[18] L. Qin, et al., Steroid receptor coactivator-1 upregulates integrin alpha expression
to promote breast cancer cell adhesion and migration, Cancer Res. 71 (2011)
1742–1751.
[19] Y.G. Man, A. Schwartz, P.H. Levine, C. Teal, P.E. Berg, BP1, a putative signature
marker for inﬂammatory breast cancer and tumor aggressiveness, Cancer
Biomark. 5 (2009) 9–17.
[20] M. Yu, Y. Wan, Q. Zou, Prognostic signiﬁcance of BP1 mRNA expression level
in patients with non-small cell lung cancer, Clin. Biochem. 41 (2008)
824–830.
[21] Y. Ide, et al., Aberrant expression of N-acetylglucosaminyltransferase-IVa
and IVb (GnT-IVa and b) in pancreatic cancer, Biochem. Biophys. Res.
Commun. 341 (2006) 478–482.
[22] J. Kotaskova, et al., High expression of lymphocyte-activation gene 3 (LAG3) in
chronic lymphocytic leukemia cells is associated with unmutated immunoglobu-
lin variable heavy chain region (IGHV) gene and reduced treatment-free survival,
J. Mol. Diagn. 12 (2010) 328–334.
[23] J. Dimberg, A. Hugander, B.M. Hall-Karlsson, A. Sirsjo, RFX-B, a MHC class II tran-
scription factor, suppressed in human colorectal adenocarcinomas, Int. J. Mol.
Med. 9 (2002) 213–216.
[24] R. Matsuyama, et al., Predicting 5-ﬂuorouracil chemosensitivity of liver metasta-
ses from colorectal cancer using primary tumor specimens: three-gene expres-
sion model predicts clinical response, Int. J. Cancer 119 (2006) 406–413.
[25] K. Kleivi, et al., Gene expression proﬁles of primary colorectal carcinomas, liver
metastases, and carcinomatoses, Mol. Cancer 6 (2007) 2.
[26] A.G. Eldridge, A.V. Loktev, D.V. Hansen, E.W. Verschuren, J.D. Reimann, P.K.
Jackson, The evi5 oncogene regulates cyclin accumulation by stabilizing the
anaphase-promoting complex inhibitor emi1, Cell 124 (2006) 367–380.
[27] R.J. Giannone, H.W. McDonald, G.B. Hurst, R.F. Shen, Y. Wang, Y. Liu, The protein
network surrounding the human telomere repeat binding factors TRF1, TRF2,
and POT1, PLoS One 5 (2010) e12407.
[28] P.S. Bradshaw, D.J. Stavropoulos, M.S. Meyn, Human telomeric protein TRF2 asso-
ciates with genomic double-strand breaks as an early response to DNA damage,
Nat. Genet. 37 (2005) 193–197.
[29] J. Furuta, Y. Nobeyama, Y. Umebayashi, F. Otsuka, K. Kikuchi, T. Ushijima, Silenc-
ing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative
promoter regions in human malignant melanomas, Cancer Res. 66 (2006)
6080–6086.
[30] C. Camisaschi, et al., LAG-3 expression deﬁnes a subset of CD4(+)CD25(high)
Foxp3(+) regulatory T cells that are expanded at tumor sites, J. Immunol. 184
(2010) 6545–6551.
[31] A.M. Schwartz, Y.G. Man, M.K. Rezaei, S.J. Simmens, P.E. Berg, BP1, a homeoprotein,
is signiﬁcantly expressed in prostate adenocarcinoma and is concordant with pros-
tatic intraepithelial neoplasia, Mod. Pathol. 22 (2009) 1–6.
[32] P.A. Fujita, et al., The UCSC Genome Browser database: update 2011, Nucleic Acids
Res. 39 (2011) D876–D882.
